Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Items 501–538 of 538
dos Santos Guilherme, M. (2023) · Gutenberg Open Science · doi:10.25358/openscience-8972
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787956
Aho, V. T. E., Houser, M. C., B., P. P. A., Chang, J., Rudi, K., Paulin, L. G., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Figshare · doi:10.6084/m9.figshare.13787941
Das gastrointestinale Mikrobiom beim idiopathischen Parkinson-Syndrom: Zentrale Rolle von Kovariaten
Cosma-Grigorov, A. (2023)
Htoo, Z. W. (2022) · K-State Research Exchange (Kansas State University) · Cited by 1
Glad, E. (2020) · Tampere University Institutional Repository (Tampere University)
Tengsl þarmaflóru mannsins og mótun/þróun sjúkdóma
Jensdóttir, G. M. (2021) · Skemman
Malattia di Parkinson e asse intestino-cervello: nuove prospettive sul microbiota intestinale
TUFILLI, V. (2024) · Electronic Theses and Dissertations Repository (University of Pisa)
Alteraciones de la microbiota intestinal en las enfermedades prion-like: Una revisión sistemática
Huertas, C. L., & Martín Burriel, I. (2023) · Zaguan (University of Zaragoza Repository)
Microbiota effects in a Pink1-/- mouse model of infection-induced Parkinson’s disease
Brouillard-Galipeau, M. (2024) · eScholarship@McGill (McGill) · doi:10.82308/44945
The Gut-Brain Axis in Parkinson’s Disease: Probiotic Interventions and Mechanistic Insights
Hasnain, M. A., Bashir, H. H., & Moon, G. (2025) · Current Topic in Lactic Acid Bacteria and Probiotics · doi:10.35732/ctlabp.2025.11.2.41
Hoffmann, P. A., Martin, J. C., Evora, A., Brillet, F., Scott, K. P., & Platt, B. (2026) · Research Square · doi:10.21203/rs.3.rs-8852210/v1
Engineered bacteria: a novel era for metabolic, cardiovascular and cerebrovascular diseases therapy
Wu, Y., Sang, R., Chen, X., & Wang, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1757348
“It has been confirmed that the abundance of Bacillus subtilis and Bacteroides fragilis decreases in PD patients (57), while the abundance of Ruminococcaceae, Spirobacteriaceae, and Clostridaceae decreases in AD patients (58).”
Viable gut bacterial metrics associated with intestinal eubiosis and dysbiosis
Naito, T., Setoyama, H., KATO-NAGAOKA, N., Shima, T., Sato, T., Moriyama-Ohara, K., Arase, S., Kurakawa, T., Horino-Higuchi, M., Tajima, S., et al. (2026) · Gut Microbes Reports · doi:10.1080/29933935.2026.2646054 · Cited by 1
Self-citationParkinson's Disease: Is It Hidden in the Gut Ecology the Ariadne's Thread Leading to Help?
Marotta, F., Ahmadi, A. M., Kushugulova, A. R., Catanzaro, R., Rastmanesh, R., Rasulova, S., & Haghsnenas, L. (2026) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70043
“This is associated with a chronic entry of LPS through the gut lining with facilitation of nitrotyrosine and coliform bacteria transepithelial penetration with significant α-synuclein staining and increase with PD progression [30–32] and reduced serum level of LPS-binding protein [31].”
Etude physiopathologique de la diffusion de la maladie de parkinson au système nerveux autonome
Leclair‐Visonneau, L. (2017) · theses.fr (ABES) · doi:10.70675/6537e18cze1c8z4bd8zad04z73a63a9ae4fe
Arotçarena, M.-L. (2019) · theses.fr (ABES) · doi:10.70675/fc7ae442z6823z43c3z8ebazd4960299833b
Écale, F. (2021) · theses.fr (ABES) · doi:10.70675/f456a090zae0fz489czb8e9z6739bf2d74ae · Cited by 1
Peptidoglycan : a key elicitor of the gut- brain axis
Fioriti, F. (2023) · theses.fr (ABES) · doi:10.70675/9e7ce0aaz9b66z467bzbc3fz6fa3bf65d9a6
Kadandelu, M., Periya, S., Rekha, P. D., & Raghu, S. V. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0144
“Since certain Clostridium bacteria generate hydrogen, which may have neuroprotective e ff ects, their reduced presence in PD patients could play a role in neurodegeneration (Hasegawa et al. 2015).”
Öztürk, C. E., Cangür, Ş., KESKİN, B. H., Ayaslı, A. A. H., DURAN, P., & Öztürk, A. (2026) · Acta Neurologica Scandinavica · doi:10.1155/ane/9266094
The ‘gut feeling’: Connecting neurodegenerative diseases and gut microbiota
Niyogi, S., & Basu, S. (2026) · The Microbe · doi:10.1016/j.microb.2026.100719
Composition and diversity of gut microbiota in non-erosive reflux disease
Wei, X., Wang, G., Wei, Y., Zhang, T., Lu, M., Xu, L., Zhang, B., & Tang, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1795756
“Additionally, an increase in the number of Lactobacillus was also observed in disease states such as type 2 diabetes mellitus and Parkinson’s disease (Hasegawa et al., 2015; Sato et al., 2014).”
Porta, M. D., Barichella, M., Pezzoli, G., & Cazzola, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093711 · Cited by 2
“While reduced LBP has been reported in PD and linked to gut inflammation [9,23], it remains unclear whether this represents a cause or a consequence of systemic immune activation.”
Zihan, R., Pengfei, L., & Cao, J. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02530-z
“…puzzle, the remaining unmediated effects of Fusobacteria-ceae are likely channeled through parallel pathways—such as LPS-driven microglial toxicity (Hasegawa et al. 2015) or short-chain fatty acid (SCFA) depletion (Cirstea et al. 2020)—underscoring the necessity for future multi-target…”
Gallegos-Altamirano, E., Jorge, C.-A., Erandi, P. F., Guevara‐Salinas, A., Emiliano, G.-V., Valeria, M.-R., Diana, Á.-L., Rodríguez‐Violante, M., Ichikawa-Escamilla, E., Yamil, R.-M. A., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106840
Cheng, Y.-K., & Chiang, H.-S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00004-1
Pirovano, E., Silva, I. P., Camacho, M., Canak, A., Aktaş, B., Crompton, D., Gökçe, E., Tan, F.-M., Marino, F., Domingos, J., et al. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106211
Higashikawa, F., & Kanno, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-52342-9
“Parkinson’s disease 16,17 and rheumatoid arthritis 18 have been implicated in the reduction of gut bacteria-derived hydrogen 15 .”
Wang, M., Sun, G., Wan, P., Wang, Z., Nie, Y., Liu, H., Geng, M., Liu, M., & Zhang, Y. (2026) · Brain Sciences · doi:10.3390/brainsci16080804
“Injection of α -syn PFF into the duodenal muscular layer was associated with local intestinal p-α -syn pathology and changes in gut microbiota composition resembling those reported in patients with PD [55].”
Hoffmann, P. A., Martin, J. C., Evora, A., Brillet, F., Scott, K. P., & Platt, B. (2026) · Research Square · doi:10.21203/rs.3.rs-10729381/v1
Braun, N. J., & Mor, D. E. (2026) · Brain Sciences · doi:10.3390/brainsci16111141
The role of the classical complement cascade in a "body-first" mouse model of Parkinson’s disease
Yudina, M. (2026) · UCL Discovery (University College London)
Tosefsky, K. N., Schaffner, S. L., Lam, J. S. T., Wang, Y. N., Keymanesh, S., Kuan, A. J., Metcalfe‐Roach, A., Cirstea, M. S., Sacheli, M., Morelli, T. F., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117981
Mehta, P., & Das, B. K. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101572
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.